Clinical Experience with Insulin Detemir: Results from the Bangladesh Cohort of Global A1chieve Study

Authors

  • Zafar Ahmed Latif Department of Endocrinology, BIRDEM ospital, 122, KaziNazrul Islam Avenue, Shahbagh, Dhaka-1000,
  • Md. Faruque Pathan Department of Endocrinology, BIRDEM ospital, 122, KaziNazrul Islam Avenue, Shahbagh, Dhaka-1000,
  • Md. Nazrul Islam Siddiqui Department of Endocrinology, Mymensingh Medical College Hospital, Mymensingh
  • MA Mannan Department of Endocrinology, Dhaka Medical College Hospital, Dhaka
  • SM Ashrafuzzaman Department of Endocrinology, BIRDEM
  • Md. Mahfuzur Rahman Novo Nordisk Pharma (Pvt.) Ltd.
  • Md. Javed Sobhan Novo Nordisk Pharma (Pvt.) Ltd.

DOI:

https://doi.org/10.3329/birdem.v3i1.17121

Keywords:

Type 2 diabetes mellitus, Levemir, Bangladesh

Abstract

Objective: To present results from the Bangladesh cohort of the A1chieve study receiving insulin detemir (Levemir) ± oral anti diabetic drugs.

Methods: Out of 1093 patients recruited from 49 sites in Bangladesh, 370 were initiated on insulin detemir (Levemir).Study visits were defined as baseline, interim (around 12 weeks from baseline) and final (around 24 weeks from baseline) visit.

Results: Glycaemic control was poor in all the groups at baseline. In the entire cohort at 24 weeks, significant reductions from baseline were observed in mean HbA1c (from 10.0 % to 7.2%, p<0.001), FPG (from 10.5 to 6.7 mmol/L, p<0.001) and PPPG (from 15.3 to 8.9 mmol/L, p<0.001) levels. Overall 45.5% of the participants achieved target HbA1c level of < 7% after 24 weeks. The rate of all hypoglycaemic events in the entire cohort reduced from 1.34 (baseline) to 0.12 events/person year after 24 weeks of insulin detemir therapy (p<0.0001). There was no clinically relevant change in body weight in insulin naïve or prior insulin users groups after 24 weeks of insulin detemir therapy.

Conclusions: The current study suggests that insulin detemir may be considered as a safe and effective option for initiating insulin therapy for type 2 diabetes in Bangladesh.

Birdem Med J 2013; 3(1): 11-18

DOI: http://dx.doi.org/10.3329/birdem.v3i1.17121

Downloads

Download data is not yet available.
Abstract
984
PDF
592

Downloads

Published

2013-11-24

How to Cite

Latif, Z. A., Pathan, M. F., Siddiqui, M. N. I., Mannan, M., Ashrafuzzaman, S., Rahman, M. M., & Sobhan, M. J. (2013). Clinical Experience with Insulin Detemir: Results from the Bangladesh Cohort of Global A1chieve Study. BIRDEM Medical Journal, 3(1), 11–18. https://doi.org/10.3329/birdem.v3i1.17121

Issue

Section

Original Articles